Most owner-run pharmacies sell for ~2.1-4.4x owner earnings (SDE). But the number a buyer trusts isn't last year's EBITDA — DIR fees and PBM reimbursement can make trailing earnings un-repeatable, and a chain may want only your script file. See where you really land.
Enter two numbers for an instant Independent Pharmacies ballpark. No signup — the real number comes from your books.
We answer each one from your books first — so you fix the story before a diligence team writes the number.
This is the dominant attack. PBM DIR fees (retroactive clawbacks) hit months after a script is filled, and reimbursement can fall below your acquisition cost on some drugs. After the Jan-2024 reform moved DIR to point-of-sale, PBM rates dropped to roughly AWP minus 18-26% (from minus 4-11% in 2023), and gross profits hit a 10-year low. A buyer rebuilds the P&L on CURRENT reimbursement, not your trailing earnings — so they normalize reported EBITDA down and won't pay your headline multiple on profit that's structurally compressed.
There are two different deals here. A chain (CVS, Walgreens) usually buys the prescription FILE plus inventory near cost and migrates your patients to an existing store — it does not take the lease, staff, or storefront goodwill. The whole-business buyer is usually another independent or a pharmacist-buyer. File value is paid per annual script (~$5-$50) and DECAYS fast if patients defect before close, so a buyer prices which deal the market will actually pay for, not the value you assume.
If the owner is the lead or only PharmD and the dispensing, clinical services, and relationships run through them, the business doesn't transfer cleanly. A buyer charges a market staff-pharmacist salary (the pharmacist-in-charge role) against your earnings before any multiple and discounts for the required owner transition and replacement-pharmacist cost — so a single-PharmD store sits at the bottom of the SDE band until staff coverage exists.
Rx margins are thin and PBM-controlled; the higher-margin front-end (OTC, retail, immunizations, clinical services) is what a buyer underwrites for real profit. A store that is nearly all-Rx has little margin cushion against reimbursement swings, and the generic-vs-brand dispensing mix drives the gross profit. A buyer reads a thin, all-Rx, generic-light store as fragile and prices it accordingly.
Heavy dependence on a few PBM/payer contracts or a single large Part D plan means one reimbursement change can swing the whole P&L. Separately, drug inventory value, expiry/obsolescence, and DEA-regulated controlled-substance records and transfer are diligence flashpoints — slow or expired stock gets marked down, and controlled-substance handling has to be clean and transferable for the deal to close.
Each lever is sized for a illustrative single-store owner-normalized cash flow on ~$5m revenue (ncpa: avg ~$5m sales/store) at thin ~2–3% net after a market staff-pharmacist wage; trailing earnings are exposed to pbm/dir-fee reimbursement compression and may not repeat — the engine uses the seller's computed sde/ebitda — about $250K EBITDA. Same number whether we frame it as “what a buyer discounts” or “what you keep by fixing it.”
A staff PharmD who can serve as pharmacist-in-charge proves the store dispenses and stays licensed without the owner behind every counter. It's the single biggest move from the bottom of the SDE band toward the operator-EBITDA market, because it lets a buyer stop charging the owner's full pharmacist wage as un-transferable labor.
adds about 0.4–0.8× to your multiple · usually takes 12–24 months
Script volume IS the asset (the file), and a rising count is the headline driver — the 2024 average was 67,601 scripts/store, up from 59,644 in 2023. Layering on immunizations, MTM/adherence packaging, compounding, and 340B contract work (where eligible) adds higher-margin, less PBM-squeezed revenue that lifts the multiple and differentiates you from a pure dispensing file.
adds about 0.2–0.5× to your multiple · usually takes 6–18 months
Generic dispensing is the gross-profit driver, and a profitable front-end (OTC, retail, services) offsets thin Rx margin and is the part a buyer can actually grow. Raising the generic-dispensing rate and building front-end margin directly improves the owner-normalized earnings the multiple is applied to — and the earnings a buyer can trust.
adds about 0.2–0.5× to your multiple · usually takes 6–18 months
Because a buyer assumes last year's gross profit won't repeat, the highest-leverage credibility move is showing your CURRENT reimbursement and payer mix, separating front-end from Rx margin, and carrying a dated, valued inventory ledger with clean controlled-substance records. It removes the markdown levers a buyer reaches for and lets them underwrite earnings they can actually defend.
adds about 0.1–0.3× to your multiple · usually takes 3–12 months
Typical impact ranges blended from lower-middle-market transaction data, sub-$50M M&A databases, and observed consolidator pricing in the $300K–$3M EBITDA band. Directional, not a guarantee — your memo computes your actual numbers from your books.
The metrics buyers grade independent pharmacies on. The diagnostic fills the “your business” column from your actual QuickBooks data.
| Metric | Independent Pharmacies benchmark | Your business | What it means |
|---|---|---|---|
| Recurring / contracted revenue | ~70% of revenue | Your data | Higher is better — the top multiple lever |
| Gross margin | ~20% | Your data | Pricing and job-costing discipline |
| EBITDA margin | ~3% | Your data | What flows to the bottom line |
| Healthy customer-concentration ceiling | top customer under 25% | Your data | Above it, buyers price the risk |
| Typical industry growth | ~3% / yr | Your data | Beating it can add to your multiple |
| Typical sale multiple | 3.4–11.5× EBITDA | Your data | Where the bidding starts; the levers above move you up |
Benchmarks are blended industry composites, service businesses $1M–$10M revenue, 2026-Q1 — directional, not a precise bar. Your memo measures you against your own books. Connect QuickBooks to fill in your numbers →
The diagnostic arrives as formats you can actually use, plus a private, scoped link to share a curated package with a specific buyer — you decide, card by card, what they see.
A branded slide deck, ready to present — for the buyer meeting, the lender, or the board.
A written diagnostic that holds up with buyers, yours to edit — plain-English summary, how we rebuilt your real earnings, every add-back listed.
Live formulas, not a dead printout — the path from raw profit to your real number, plus the cash-tied-up scenarios a buyer can stress-test.
Pharmacy M&A splits into two deals: chains buy the prescription FILE (plus inventory near cost); independents and pharmacist-buyers buy the WHOLE going concern. The big-chain roll-up has cooled — CVS and Walgreens spent recent years shrinking store counts (Walgreens went private under Sycamore Partners in 2025), buying script files from failed competitors, not rolling up independents. So don't assume a chain bidding war — a chain wants the file, only if it fits its footprint.
Read-only, through Intuit. We never write to your books. About 5 minutes.
Just what the books can’t show — agreements, key accounts, who runs the crews.
Buyer-readiness score, normalized EBITDA, value range and top flags — instantly.
The full engine, all three deliverables, the dashboard and the buyer deal room.
Read-only, enforced in our code: every call we make to QuickBooks is a read. Nothing leaves unless you choose to share it.
Disconnect or delete anytime. Read our privacy policy →
Start with the free preview. Pay once — $499 — only when you want the full memo. No subscription, no per-seat pricing.
Most Independent Pharmacies businesses in the $1M–$10M revenue range trade at roughly 3.4× to 11.5× normalized EBITDA, with a typical deal near 6.5×. Smaller, owner-dependent shops sit at the low end; larger, manager-run businesses with recurring revenue reach the top. Your actual number depends on your books — that's what the diagnostic computes, blending recent lower-middle-market closings, main-street marketplace sales, and academic M&A survey data.
Because in pharmacy, last year's profit often doesn't repeat. PBM reimbursement and DIR fees (retroactive clawbacks) can push a drug's payment below what you paid for it, and the 2024 reimbursement environment dropped to roughly AWP minus 18-26%, sending gross profits to a 10-year low. A careful buyer rebuilds your P&L on current reimbursement and normalizes reported EBITDA down — so anchoring your price on trailing earnings usually leads to disappointment. Showing your current reimbursement and payer mix is the best way to defend the number.
It depends on whether the going-concern earnings are real and repeatable. A healthy whole-business sale (priced on SDE or EBITDA) usually beats a bare script-file sale — but if your earnings are thin and PBM-compressed, the realistic buyer may only want the file: a chain pays a set amount per annual script (~$5-$50), buys inventory near cost, and doesn't take the lease, staff, or storefront. File value also decays if patients leave before close, so timing and patient retention matter.
Yes — it's a real discount on smaller stores. If you're the lead or only PharmD and the dispensing and relationships run through you, a buyer charges a market staff-pharmacist salary against your earnings (the pharmacist-in-charge role) before any multiple and discounts for the owner transition. Hiring a staff pharmacist who can hold the PIC role is the highest-leverage move you can make on your multiple, because it shows the business runs without you.
Sixty seconds. Four numbers. No signup, no email. Just a real answer.